Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Royalty Pharma plc (RPRX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B | $2.12B | $1.81B | $1.79B |
| Research & development | $452.0M | $2.0M | $52.0M | $177.1M | $200.1M | $26.3M | $83.0M | $392.6M |
| Operating income | $1.56B | $1.29B | $1.49B | $307.1M | $1.43B | $1.60B | $2.62B | $1.36B |
| EBITDAderived | — | $1.29B | $1.49B | — | — | — | — | — |
| Net income | $770.9M | $859.0M | $1.13B | $42.8M | $619.7M | $975.0M | $2.35B | $1.38B |
| Basic EPSper diluted share | $1.79 | $1.92 | $2.54 | $0.10 | $1.49 | $1.32 | — | — |
| Diluted EPSper diluted share | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 | $1.32 | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 24, 2026Form 4 · 10b5-1 | Urist MarshallEVP, Research & Investments | SellClass A Ordinary Shares | 9.1K | $55.18 | $502.0K | 9.1K |
| Jun 23, 2026Form 4 · 10b5-1 | Hite ChristopherEVP & Chairman, Partnering | SellClass A Ordinary Shares · indirect | 117.6K | $54.47 | $6.41M | 559.4K |
| Jun 23, 2026Form 4 · 10b5-1 | Hite ChristopherEVP & Chairman, Partnering | SellClass A Ordinary Shares · indirect | 32.4K | $54.11 | $1.75M | 677.0K |
| May 26, 2026Form 4 · 10b5-1 | Coyne Terrance P.EVP & CFO | SellClass A Ordinary Shares · indirect | 64.4K | $53.98 | $3.48M | 0 |
| May 20, 2026Form 4 · 10b5-1 | Urist MarshallEVP, Research & Investments | SellClass A Ordinary Shares | 13.7K | $52.75 | $721.8K | 18.2K |